Slide 1: Innovation in gene synthesis & delivery
Innovation in gene synthesis & delivery June 2022 1
Slide 2: Presenters
Presenters Dr. Heikki Lanckriet, PhD. CEO & CSO David Roth CFO 2
Slide 3: Disclaimer
Disclaimer This document is intended for shareholders, prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estim
Slide 4: Agenda
Agenda ➢ Business Overview ➢ Technologies ➢ Commercial landscape ➢ Our product offering ➢ Progress & future Objectives ➢ Achievements ➢ July 2021 Objectives ➢ Look to the future ➢ Financial Position ➢ 2021 Results ➢ 2022 Position ➢ Shareholder structure ➢ Summary Investor Presentation 4
Slide 5: Business Overview
—€) Business Overview , ON ‘Ldbasebio
Slide 6: Technologies
Technologies Disruptive platforms for gene therapies and vaccines DNA Synthesis Proprietary synthetic DNA products and technology for use in cell & gene therapies and vaccines $12B Synthetic Biology Market Non Viral 21% 5YFWD CAGR Delivery Proprietary, targeted non-viral vectors for delivery of biol
Slide 7: Technologies
Technologies DNA Synthesis Synthetic DNA will: - alleviate the bottleneck and long lead times of plasmid DNA manufacturing - provide safer and more flexible DNA products, accelerating therapy development. Non-Viral Delivery Targeted and non-viral delivery such as provided by our Hermes™ technology w
Slide 8: Commercial Landscape: synthetic DNA
Commercial Landscape: synthetic DNA •mRNA is produced from DNA using in vitro transcription mRNA vaccines •Presently over 3,500 therapies and viral vector in development (gene based therapies therapies, RNA therapies, cell pipeline drive therapies, vaccines) demand Alternative synthetic DNA •Market
Slide 9: Commercial Landscape: payload delivery
Commercial Landscape: payload delivery •Lipid nanoparticles: potent but with preferential uptake in the liver •Licensing arrangements for LNPs can be challenging for biotech start ups COVID mRNA vaccines validated commercial potential of non-viral delivery Viral vectors continue to dominate the cell
Slide 10: 4basebio product offering
4basebio product offering 10
Slide 11: Benefits of 4basebio DNA products
Benefits of 4basebio DNA products 11
Slide 12: Benefits of 4basebio Hermes delivery platform
Benefits of 4basebio HermesTM delivery platform 12
Slide 13: Progress to date
—Q Progress to date , ON 2:4basebio 13
Slide 14: Developments & Achievements
Developments & Achievements Scaled DNA platform to commercial Filed levels multiple +£30m patents on available in 4bbDNA cash and and debt Hermes™ Built 1x RuO TECHNOLOGY and 7x GMP production suites Validated DNA for use in AAV, First sales of RESOURCING DNA mRNA and vaccines products Team doubled
Slide 15: Revisiting July 2021: Near Term Objectives
Revisiting July 2021: Near Term Objectives Synthetic DNA Validated DNA across Non-viral nanoparticles multiple applications Validate packaging and Manufacturing including IVT mRNA, AAV, DNA vaccines, CAR-T, gene delivery of 4basebio DNA Commenced build out in therapy and gene editing products
Slide 16: Journey to GMP
Journey to GMP Q3 2022 Q1 2023 •Build out of •HQ production •GMP certified completed Runs •First DNA •Release GMP •Complete production runs •Test audit for compliant Qualification compliance batches Q2 2022 Q4 2022 H2 2023 Investor Presentation 16
Slide 17: Product Grades
Product Grades *Good Manufacturing Practice (GMP) is a system for ensuring that products are consistently produced and controlled according to quality standards. Regulated by the MHRA – Medicines & Healthcare products Regulatory Agency Investor Presentation 17
Slide 18: Plans & Objectives for 2022-2023
Plans & Objectives for 2022-2023 Continue to innovate and file IP novel DNA GMP products compliance in 2022 TECHNOLOGY Utilise existing financial resources Hermes to in-vivo for Commercial range of PRODUCTION Expansion indications (BD, PM & legal GMP Drive accredited RESOURCING validation in 2023 pr
Slide 19: Timelines
Timelines ➢ Longer term ➢ Near term ➢ Become a CDMO for the supply of synthetic DNA across multiple applications ➢ advance sales of DNA products and Hermes™ services work ➢ Progress multiple indications through IND and potentially into clinical trials ➢ Progress collaborations with partners ➢ Licenc
Slide 20: Financial Position
—€)} Financial Position , ON 2:4basebio 20
Slide 21: Financial Results 2021
Financial Results 2021 ➢ Reported operating loss of £3.5m ➢ Cash burn of £4.7m in 2021: ➢ Operating cash burn £2.7m ➢ Tangible asset additions £0.9m ➢ Capitalised development spend of £0.6m ➢ Financing £0.5m ➢ Closed 2021 with £9.6m cash on hand 21
Slide 22: Financial Position 2022
Financial Position 2022 ➢ Cash burn set to increase in 2022 to ➢ fund ongoing research and development ➢ scaling of operational team ➢ Retain €25m loan facility with 2Invest AG, major shareholder ➢ No capital increase presently foreseen 22
Slide 23: Shareholder structure
Shareholder structure 2Invest AG, 29.8% Other, 33.6% ➢ Supportive shareholders ➢ Keen to introduce life sciences specialist David Roth, 2.5% Joseph Fernandez, 3.6% Deutsche Balaton Group, 20.3% Dr Heikki Lanckriet, 10.2% 23
Slide 24: Summary
Summary Disruptive technologies in rapidly growing market Rapid progress to Well funded commercialisation since 2020 Shareholder value Secured first GMP certification commercial targeted in 2023 commitments in 2022 GMP compliance targeted for 2022 24
Slide 25: www.4basebio.com info@4basebio.com
www.4basebio.com info@4basebio.com 25